Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL +0.71%73 EV-to-EBITDA is 4.77 as of Sep. 16, 2026, which is 1% above its 10-year median of 4.70. GuruFocus rates ASX:ACL with a GF Score™ of 73/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 8 warning signs investors should review. Among 128 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 90.62% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Australian Clinical Labs's enterprise value is A$842.6 Mil.
Australian Clinical Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was A$176.5 Mil. Therefore, Australian Clinical Labs's EV-to-EBITDA for today is 4.77.
The historical rank and industry rank for Australian Clinical Labs's EV-to-EBITDA or its related term are showing as below:
ASX:ACL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.26 Med: 4.7 Max: 6.48
Current: 4.78
During the past 6 years, the highest EV-to-EBITDA of Australian Clinical Labs was 6.48. The lowest was 2.26. And the median was 4.70.
ASX:ACL's EV-to-EBITDA is ranked better than 90.62% of 128
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.015
vs ASX:ACL: 4.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Australian Clinical Labs (ASX:ACL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Australian Clinical Labs's PE Ratio (TTM) for today is calculated as:
Australian Clinical Labs's share price for today is A$2.84.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.123.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACL vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's EV-to-EBITDA falls into.
Australian Clinical Labs's current Enterprise Value is A$842.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was A$176.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a EV-to-EBITDA of 4.77 as of Sep. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Australian Clinical Labs. This is near median its historical median of 4.70. Over the past decade, Australian Clinical Labs' EV-to-EBITDA has ranged from 2.26 to 6.48. According to the industry distribution chart, Australian Clinical Labs ranks #12 out of 128 companies in the Medical Diagnostics & Research industry, placing it in the top 9.4%.
Is Australian Clinical Labs' EV-to-EBITDA too high?
Australian Clinical Labs' current EV-to-EBITDA of 4.77 is near median its 10-year median of 4.70. Over the past 10 years, this metric has ranged from a low of 2.26 to a high of 6.48. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.02. Australian Clinical Labs' value of 4.77 is 70.2% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #12 out of 128 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #12 out of 128 companies for EV-to-EBITDA. This places Australian Clinical Labs in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 16.02. Australian Clinical Labs' value of 4.77 is 70.2% below this benchmark. Historically, Australian Clinical Labs' own EV-to-EBITDA has ranged from 2.26 to 6.48 over the past decade. While the company's 10-year median is 4.70 vs. the industry median of 16.02, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.02, based on 128 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current EV-to-EBITDA of 4.77 is 70.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Australian Clinical Labs. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current EV-to-EBITDA is 4.77, which is near median its own 10-year median of 4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.84 — trading 3.7% below its estimated fair value. The current EV-to-EBITDA is 4.77, which is near median its 10-year median of 4.70 and 70.2% below the Medical Diagnostics & Research industry median of 16.02. Australian Clinical Labs' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current EV-to-EBITDA is 4.77 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.84 is trading 3.7% below its estimated GF Value™ of A$2.95.
GuruFocus considers Australian Clinical Labs to be Fairly Valued.
Key valuation signals for ASX:ACL:
EV-to-EBITDA: 4.77 (near median its 10-year median of 4.70)
GF Value™: A$2.95 vs. price of A$2.84 (3.7% below fair value)
Industry Position: 70.2% below the Medical Diagnostics & Research median (#12 of 128)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
73GF Score
Get the complete analysis for ASX:ACL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
